Concentrate for solution for infusion 120mg, 400mg

 RAG for NICE TA806: TA806 Belimumab for treating lupus nephritis (terminated appraisal) 

Tablets 60mg, 90mg, 120mg

Rheumatology initiation only

Suppositories 12.5mg, 25mg, 50mg, 100mg

For short term treatment of post-op pain, renal colic and lithotripsy only

Tablets e/c 25mg, 50mg
Dispersible tablets 50mg
 
For short term use in breastfeeding mothers only

For short term treatment of post-op pain (Akis^®)
 

Injection 75mg/1mL

Morecambe bay only

Injection 80mg/2mL, 120mg/3ml, 40mg/ml 

Injection
(Methylprednisolone 80mg/2mL with lidocaine 20mg/2mL)

Pre-filled syringe/pen 160mg

ICB Commissioned

Pre-filled pen 150mg. 200mg
Pre-filled syringe 150mg, 200mg

Tablets 125mg

Tablets 200mg, 300mg

Intravenous infusion 250mg
S/C injection 125mg prefilled syringe pre-filled pen 

Usually supplied to patients by a home delivery company

REQUIRES BLUETEQ APPROVAL

S/C injection 40mg prefilled syringe and pen

Usually supplied to patients by a home delivery company

REQUIRES BLUETEQ APPROVAL

Solution for injection pre-filled syringes  100mg/0.67mL

Tablets 10mg, 20mg, 30mg

Tablets 25mg, 50mg

S/C injection 200mg prefilled syringe pre-filled pen 

Usually supplied to patients by a home delivery company

REQUIRES BLUETEQ APPROVAL

Capsules 25mg, 50mg, 100mg

S/C injection 25mg, 50mg vial with diluent and prefilled syringe pre-filled pen 

usually supplied to patients by a home delivery company

REQUIRES BLUETEQ APPROVAL

S/C injection 50mg, 100mg, prefilled syringe pre-filled pen 

Usually supplied to patients by a home delivery company

REQUIRES BLUETEQ APPROVAL

Solution for injection in pre-filled pen 100mg/1ml

Intravenous infusion 100mg, 120mg/ml pre-filled pen

REQUIRES BLUETEQ APPROVAL

80mg solution for injection prefilled syringe; prefilled pen

Tablets 10mg, 20mg

Tablets 2.5mg

S/C 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 17.5mg, 20mg, 22.5mg, 25mg and 30mg


Methotrexate should be prescribed once weekly as a single dose on the same day each week.
If oral methotrexate is prescribed only use the 2.5 mg strength.
See hospital policy for prescribing and supply of oral methotrexate

solution for injection pre-filled syringes, solution for injection pre-filled pen 150mg/mL

Concentrate for intravenous infusion 500mg/50mL


REQUIRES BLUETEQ APPROVAL

150mg/ml pre-filled pens/syringes

Concentrate for intravenous infusion (20mg/mL) 80mg, 200mg, 400mg vials

Soution for injection in pre-filled syringe 162mg

Solution for injection in pre-filled pen 162mg

Usually supplied to patients by a home delivery company

REQUIRES BLUETEQ APPROVAL

Subcutaneous injection 45mg, 90mg prefilled syringes and 45mg/0.5ml vials

Tablets 2mg, 4mg

Tablets 100mg, 200mg

Tablets 5mg

MR Tablets 11mg

   CCG commissioned for TA547

Prolonged release tablets 15mg

 For NICE TA665: upadacitinib for treating severe rheumatoid arthritis - see link below

 For NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs - see link below

 For NICE TA829: Upadacitinib for treating active ankylosing spondylitis - see link below 

For NICE TA861 Upadacitinib for treating active non-radiographic axial spondyloarthritis - see link below

E/C tablets 500mg

Other dose forms of sulfasalazine - see section 1.5, non e/c tablets and liquid are not licensed for rheumatoid arthritis

Solution for injection  94.5mg/0.5mL

 Tertiary Centre only for NICE HST25 Lumasiran for treating primary hyperoxaluria type 1 - See link below

Tablets 500 micrograms

Granules for oral suspension 1000mg, 125mg, 250mg

Ataluren for treating Duchenne muscular dystrphy with a nonsense mutation in the dystrophin gene (replaces HST3) - likely to be tertiary centre only

Solution for injection vials 12mg/5ml

Powder for oral solution 0.75mg/mL

Tablets 60mg

Restricted to an initial 4-week trial for treatment of moderate to severe spasticity in adults with multiple sclerosis in line with NICE NG144. Treatment may be continued after the 4-week trial as long as the patient has had at least a 20% reduction in spasticity-related symptoms

  for Refractory neuropathic pain

Capsules 25mg

Capsules 167mg

Tablets 2mg, 4mg

Consultant initiation only

Rubefacients (excluding topical NSAIDs and capsaicin) are classified as BLACK (Not to be prescribed) as per national guidelines on items which should not routinely be prescribed in primary care.

Examples include: Algisal, Deep Heat, Transvasin

In hospital Deep Heat cream may be used for aiding the collection of arterial blood gases.

gel 5%

In Primary Care prescribe as Fenbid gel

gel 10%

Primary Care only  - prescribe as Fenbid Forte gel

Cream 0.025%

This medicine has been assigned a temporary Do not prescribe RAG rating due to a temporary lack of availability.

Cream 0.075%

This medicine has been assigned a temporary Do not prescribe RAG rating due to a temporary lack of availability.

Patch 179mg (8%)

Treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain.

For specialist use only

 for acute tibia fractures in adults (licensed)

 for non-union long bone fractures (unlicensed)